- Home
- RMBS vs IOVA Comparison
RMBS vs IOVA Comparison
Compare RMBS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBS
- IOVA
- Stock Information
- Founded
- RMBS 1990
- IOVA 2007
- Country
- RMBS United States
- IOVA United States
- Employees
- RMBS N/A
- IOVA N/A
- Industry
- RMBS Semiconductors
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMBS Technology
- IOVA Health Care
- Exchange
- RMBS Nasdaq
- IOVA Nasdaq
- Market Cap
- RMBS N/A
- IOVA 1.0B
- IPO Year
- RMBS 1997
- IOVA N/A
- Fundamental
- Price
- RMBS $52.22
- IOVA $3.61
- Analyst Decision
- RMBS Strong Buy
- IOVA Strong Buy
- Analyst Count
- RMBS 5
- IOVA 9
- Target Price
- RMBS $80.00
- IOVA $18.22
- AVG Volume (30 Days)
- RMBS 1.2M
- IOVA 10.0M
- Earning Date
- RMBS 04-28-2025
- IOVA 05-08-2025
- Dividend Yield
- RMBS N/A
- IOVA N/A
- EPS Growth
- RMBS N/A
- IOVA N/A
- EPS
- RMBS 1.65
- IOVA N/A
- Revenue
- RMBS $556,624,000.00
- IOVA $164,070,000.00
- Revenue This Year
- RMBS $25.99
- IOVA $182.20
- Revenue Next Year
- RMBS $13.50
- IOVA $62.10
- P/E Ratio
- RMBS $31.65
- IOVA N/A
- Revenue Growth
- RMBS 20.71
- IOVA 13698.99
- 52 Week Low
- RMBS $37.42
- IOVA $2.70
- 52 Week High
- RMBS $69.15
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- RMBS 55.27
- IOVA 54.38
- Support Level
- RMBS $43.21
- IOVA $2.89
- Resistance Level
- RMBS $49.24
- IOVA $3.43
- Average True Range (ATR)
- RMBS 3.28
- IOVA 0.30
- MACD
- RMBS 0.91
- IOVA 0.10
- Stochastic Oscillator
- RMBS 95.66
- IOVA 95.60
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.